Recombinant Human DEFB4A protein

中文名： 防御素β4A(DEFB4A)重组蛋白
别名： DEFB4A；DEFB102；Defensin beta 4A

货号: PA1000-3876

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>98%SDS-PAGE.
种属	Human
靶点	DEFB4A
Uniprot No	O15263
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	24-64aa
氨基酸序列	GIGDPVTCLK SGAICHPVFC PRRYKQIGTC GLPGTKCCKK P
预测分子量	4.3 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于DEFB4A重组蛋白的模拟参考文献示例(注：文献信息为示例性概括，非真实存在)：

---

1. **《重组人β-防御素4A(DEFB4A)的抗菌活性研究》**

- 作者：Smith A, et al.

- 摘要：研究通过大肠杆菌表达系统成功制备重组DEFB4A蛋白，证实其对革兰氏阴性菌(如大肠杆菌)和真菌(如白色念珠菌)具有显著抑菌活性，并揭示了其通过破坏微生物膜结构发挥作用的机制。

2. **《DEFB4A重组蛋白在银屑病模型中的免疫调节作用》**

- 作者：Lee J, et al.

- 摘要：通过哺乳动物细胞表达纯化DEFB4A重组蛋白，发现其可通过激活角质形成细胞的CCR6受体促进趋化因子分泌，在银屑病小鼠模型中减轻炎症并加速表皮屏障修复。

3. **《重组DEFB4A的稳定表达及其在口腔感染治疗中的应用》**

- 作者：Chen W, et al.

- 摘要：优化了DEFB4A在毕赤酵母中的分泌表达工艺，证明重组蛋白对口腔致病菌(如变形链球菌)具有高效抑制作用，并在动物实验中显著降低龋齿发生率。

4. **《DEFB4A重组蛋白与肿瘤微环境调控的关联研究》**

- 作者：Garcia R, et al.

- 摘要：发现DEFB4A重组蛋白可通过结合肿瘤细胞表面TLR4受体，增强巨噬细胞的抗肿瘤M1型极化，在体外实验中抑制结直肠癌细胞迁移。

---

注：以上内容为根据DEFB4A相关研究领域常见方向的模拟概括，实际文献需通过学术数据库检索确认。

背景信息

DEFB4A, also known as human beta-defensin 4A, is a small cationic peptide belonging to the defensin family, a class of evolutionarily conserved antimicrobial proteins integral to innate immunity. Encoded by the DEFB4A gene located on chromosome 8p23.1. it is primarily produced by epithelial cells and immune cells at mucosal surfaces, such as the skin, respiratory tract, and urogenital tissues. Functionally, DEFB4A exhibits broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses by disrupting microbial membranes through electrostatic interactions. Beyond direct pathogen neutralization, it modulates immune responses by recruiting dendritic cells, T cells, and neutrophils via chemotaxis and activating signaling pathways through receptors like CCR6.

Recombinant DEFB4A protein is engineered using biotechnological methods, often expressed in Escherichia coli or mammalian cell systems to ensure proper folding and post-translational modifications. Its production involves cloning the DEFB4A gene into expression vectors, followed by purification techniques such as affinity chromatography. The recombinant form retains the biological properties of the native peptide, making it valuable for research and therapeutic exploration. Studies highlight its potential in treating infections, chronic wounds, and inflammatory diseases, as well as its role in cancer immunotherapy due to its ability to enhance tumor antigen presentation.

However, challenges remain, including optimizing stability in vivo and understanding context-dependent pro-inflammatory or anti-inflammatory effects. Research continues to unravel its dual roles in host defense and disease pathology, positioning recombinant DEFB4A as a promising candidate for multifunctional therapeutic applications.